Orexin expression in different prostate histopathologic examinations: Can it be a marker for prostate cancer? A preliminary result

dc.contributor.authorMehmet Başar M.
dc.contributor.authorHan Ü.
dc.contributor.authorÇakan M.
dc.contributor.authorAlpcan S.
dc.contributor.authorBaşar H.
dc.date.accessioned2020-06-25T15:17:23Z
dc.date.available2020-06-25T15:17:23Z
dc.date.issued2013
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjective: The aim of this study was to evaluate the expression of the orexin receptor in different prostate pathologies, including prostate adenocarcinoma, benign prostate hyperplasia and chronic prostatitis. Material and methods: A total of 90 patients (mean age 64.01±7.2 years) were enrolled in the study. The patients were divided into three groups of equal numbers based on their histopathologic findings: prostate cancer (Group 1), benign prostate hyperplasia (Group 2) and chronic prostatitis (Group 3). All the tissues were incubated with a primary antibody recognizing the Orexin receptor. The specific cytoplasmic immunoreactivity of the Orexin receptor was semiquantitatively scored for intensity and distribution based on a grading scale. The staining intensity and orexin expression were evaluated using Pearson ?2 test. Results: A heterogeneous staining pattern of the Orexin receptor was observed between the groups. The expression rates were 90% (27/30) in Group 1, 53.3% (16/30) in Group 2 and 26.7% (8/30) in Group 3. While 5 patients (9.3%) in Group 1 showed strong staining, all samples from the other 2 groups showed only weak staining. There were significant differences in staining intensity between the three groups. The expression and distribution of the Orexin receptor was more widespread in Group 1 than in the other groups and was higher in patients with poorly differentiated malignancy. However, there was no significant difference based on Gleason score. Conclusion: Orexin receptors are found in human prostate tissues and their expression is widespread in prostate cancer and in patients with a higher Gleason score. Therefore, we believe that Orexin immunoreactivity can be considered to be an indicator of poor prognosis and of poorly differentiated prostate cancer cases. © 2013 by Turkish Association of Urology.en_US
dc.identifier.citationBaşar, M. M., Han, Ü., Çakan, M., Alpcan, S., Başar, H. (2013). Orexin expression in different prostate histopathologic examinations: Can it be a marker for prostate cancer? A preliminary result. Türk Üroloji Dergisi/Turkish Journal of Urology, 39(2), 78 - 83.en_US
dc.identifier.doi10.5152/tud.2013.023
dc.identifier.endpage83en_US
dc.identifier.issn13005804
dc.identifier.issue2en_US
dc.identifier.pmid26328085
dc.identifier.scopus2-s2.0-84878081825
dc.identifier.scopusqualityN/A
dc.identifier.startpage78en_US
dc.identifier.trdizinid152576
dc.identifier.urihttps://doi.org/10.5152/tud.2013.023
dc.identifier.urihttps://hdl.handle.net/20.500.12587/2343
dc.identifier.volume39en_US
dc.identifier.wosWOS:000420573500003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAVESen_US
dc.relation.ispartofTurk Uroloji Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOrexin Aen_US
dc.subjectOrexin Ben_US
dc.subjectProstateen_US
dc.subjectProstate canceren_US
dc.titleOrexin expression in different prostate histopathologic examinations: Can it be a marker for prostate cancer? A preliminary resulten_US
dc.title.alternativeFarklı prostat histopatolojilerinde oreksin varlığı: Prostat kanserinde bir belirteç olabilir mi? Ön çalışmaen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
01f167eb-b101-49e4-99fc-e24d782ce2f2.pdf
Boyut:
425.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text